Spandana returns to profit in Q1: consolidated PAT ₹11.9 Cr vs ₹360 Cr year-ago loss
revenue -5.51% · margins expanding
₹283.91 Cr
-5.51% YoY
₹11.88 Cr
3.92%
+103.9pp YoY
₹1.49
Spandana Sphoorty swung back to profit in Q1 FY27, reporting consolidated PAT of ₹11.88 Cr against a ₹360.21 Cr loss in the year-ago quarter and ₹5.27 Cr in the March quarter; standalone PAT was ₹16.09 Cr. The turnaround is a credit-cost story, not a topline one — revenue from operations actually fell 5.5% YoY to ₹283.91 Cr (though up 9.3% QoQ from ₹259.69 Cr), reflecting a smaller loan book after last year's microfinance stress.
Q1 FY-2027 vs prior quarters
The swing sits almost entirely on the impairment line: consolidated impairment on financial instruments was a ₹1.30 Cr write-back this quarter versus a ₹422.17 Cr charge in Q1 FY26 — the single item that had driven the year-ago loss. Finance costs eased to ₹132.08 Cr (from ₹153.75 Cr) and employee costs to ₹106.22 Cr (from ₹145.72 Cr), collapsing total expenses to ₹285.66 Cr from ₹785.01 Cr. Net profit margin recovered to ~3.9% from 1.9% in Q4, and PBT rose to ₹17.56 Cr from ₹8.02 Cr sequentially. There is no current tax; the ₹5.68 Cr charge is deferred, with the group carrying a ₹634 Cr DTA on carried-forward losses.
The stock went into the print at ₹292.25, up 15.3% over the past month of trading.
For context: this is the highest quarterly PAT in the last 5 quarters on our records; PAT has now risen for 4 consecutive quarters.
Management guides for strong AUM growth to INR 6,500 crores by the end of FY27, implying ~48% growth, fueled by adding 7 lakh new borrowers and ramping up monthly disbursals to INR 550-600 crores. They aim to remain profitable while maintaining a high X-bucket collection efficiency of around 99.5%. Strategically, the f
— This quarter: met
Against management's last-concall guidance — remain profitable while driving AUM to ₹6,500 Cr by FY27-end (~48% growth) on 7 lakh new borrowers and ₹550-600 Cr monthly disbursals — this print delivers on the profitability commitment, but the YoY revenue decline shows the AUM-growth leg is not yet visible in the P&L. Asset quality looks repaired: Stage III at 2.91% (net 0.56%), PCR 80.82%, CRAR 28.65%, net worth ₹2,208 Cr. The quarter also carried heavy board churn — Chairperson Abanti Mitra passed away on July 14 and the board appointed independent director Dipali Hemant Sheth as Non-Executive Chairperson alongside these results — while the company is re-evaluating merger terms for consolidating 99.92%-owned subsidiary Criss Financial, whose ~₹4 Cr quarterly loss is why consolidated PAT trails standalone. No reliable street consensus was available for the quarter.
W1
AUM/disbursal trajectory vs the ₹6,500 Cr FY27 guidance — revenue fell 5.5% YoY, so watch whether ₹550-600 Cr monthly disbursals start lifting the book next quarter.
W2
Durability of near-zero credit cost: the ₹1.30 Cr impairment write-back depends on Stage III staying near 2.91% and X-bucket collection holding ~99.5%.
W3
Criss Financial merger re-evaluation and its ~₹4 Cr quarterly drag on consolidated PAT.
Clean digital PDF, headers unambiguous, both statements tie (rev+oth=totInc; PBT-tax=PAT). NBFC (microfinance): no revenue-from-ops single line — sum of interest income + fair-value gains used. Tax is 100% deferred (no current tax); group holds ~₹634 Cr DTA on ₹522.65 Cr carried-forward FY25/26 losses. Consolidated PAT (₹11.88 Cr) < standalone (₹16.09 Cr) due to ~₹4 Cr net loss at subsidiary Criss Financial (99.92%). NCI negligible (<₹1 lakh). Year-ago loss driven by ₹422.17 Cr impairment charge, now a ₹1.30 Cr write-back.
Informational and educational content only. Not investment advice.